{"slug":"mgf","seoKey":"mgf","displayName":"Mechano Growth Factor (MGF)","codes":[],"synonyms":["MGF","IGF-1Ec","IGF-1 Ec isoform","IGF-IEb","mechano growth factor","MGF-24aa-E peptide","MGF-C25E","MGF E peptide","E-domain peptide","Ec peptide","Goldspink-MGF","MGF R23H"],"legalClass":"research_chemical","identifiers":{"formula":"C121H194N40O40","molecularWeight":2849.12,"sequence":"YQPPSTNKNTKSQRRKGSTFEEHK"},"approvals":[{"market":"US","status":"not_approved","note":"Not approved, and not a component of any approved medicine. Four independent negative findings on 2026-09-16, each with a working control query: the approvals database and the labelling endpoint both returned NOT_FOUND for the active ingredient 'MECHANO GROWTH FACTOR' while the control 'MECASERMIN' returned a biologics licence and three labels; the labelling archive returned nothing for 'mecha' and one record for the control. The compounding position needs stating precisely, because it is not a blank. Plain mechano growth factor is carried on the nomination list for bulk substances under section 503A, in the version updated 2026-05-14, in category 3, nominated without adequate support. The pegylated form went the other way: it was placed among the substances that may present significant safety risks, the agency stating that it had identified no human exposure data for it by any route, and that nomination was then withdrawn. Neither route leads to a lawful medicine, and neither is an authorisation. A research-use-only label changes nothing: goods marketed for human use are treated as unapproved new drugs.","date":"2026-05-14","source":"https://www.fda.gov/media/94155/download"},{"market":"EU","status":"not_approved","note":"No authorisation. The official medicines data export was downloaded on 2026-09-16 and searched in full: the string 'mechano' returned no match anywhere in the dataset, while the control 'mecasermin' returned three rows for the approved insulin-like growth factor product, with its procedure number and its rare-growth-disorder indication. The regulator's own site search is not evaluable without scripting; the data export replaces it fully, so this is a verified negative finding rather than an inferred one.","source":"https://www.ema.europa.eu/en/medicines"},{"market":"DE","status":"not_approved","note":"Not an authorised medicine, and named directly in criminal law. Since there is neither a central European authorisation nor a national finished product, every injectable preparation sold under the name is an unauthorised medicinal product, and advertising it to the public is prohibited. The second level matters more. The annex to section 2(3) of the anti-doping act lists, in section II.3 on growth factors and growth factor modulators, the words 'Mechano Growth Factor (MGF) und MGF-Varianten', between the entries for mecasermin and its analogues on one side and thymosin beta-4 on the other; the closing clause of the annex extends the list to salts, esters, ethers, isomers, mixtures of isomers, complexes and derivatives. The accompanying quantity regulation of 2023-03-10 sets the non-trivial quantity at 3 mg, one of the lowest figures in the whole schedule, against 60 mg for mecasermin, 100 mg for thymosin beta-4 and 16 mg for somatropin. The phrase 'und MGF-Varianten' deliberately covers the R23H analogue, C-terminally amidated forms and the pegylated form, so the question whether the material bought matches the body's own sequence does not arise.","date":"2023-03-10","source":"https://www.gesetze-im-internet.de/antidopg/anlage.html"},{"market":"UK","status":"not_approved","note":"Two separate findings. First, there is no authorised product; IMPORTANT CAVEAT: the products register serves its results by script and its interface endpoints answered with an error on 2026-09-16, so this part rests on the absence of any international non-proprietary name and on the matching negative findings in the European, United States and Canadian registers rather than on a register extract. Second, and this part was read directly in the statute: the controlled-drugs schedule lists among its peptide hormones chorionic gonadotrophin, non-human chorionic gonadotrophin, somatotropin, somatrem and somatropin, and names no growth factor at all. Mechano growth factor is therefore not a controlled drug here, but an unlicensed medicine under the human medicines regulations.","source":"https://www.legislation.gov.uk/ukpga/1971/38/schedule/2"},{"market":"AU","status":"scheduled","note":"The strictest of the markets checked, and the classification is a derivation rather than a direct listing. The poisons standard of June 2026 does not contain the words mechano growth factor or MGF anywhere in its full text. It places 'INSULIN-LIKE GROWTH FACTOR I.' and 'INSULIN-LIKE GROWTH FACTORS except when separately specified in this Schedule' in schedule 4, and the substance index records against that class an additional entry at appendix D, clause 5, item 24, headed poisons for which possession without authority is illegal. Mechano growth factor is by definition a splice variant of insulin-like growth factor 1, and both the anti-doping list and German law place it in the same rubric, so the class term captures it. The derivation is well founded; it remains a derivation. Its consequence is not: possession without a prescription, and not only supply, is unlawful.","date":"2026-05-28","source":"https://www.legislation.gov.au/F2026L00633/asmade"},{"market":"CA","status":"not_approved","note":"Not approved, with no entry in the drug product database. The active-ingredient query returned an empty array for 'mechano' on 2026-09-16, and a second query for 'growth factor' was empty as well, so no authorised active ingredient in this country carries those words in its name at all. The control query for mecasermin returned one record with its drug identification number and a last update of 2026-07-31, so the interface was working and the negative finding is verified.","source":"https://health-products.canada.ca/api/drug/activeingredient/?ingredientname=mechano"},{"market":"CH","status":"not_approved","note":"No authorisation. IMPORTANT CAVEAT: the regulator's export of authorised human medicines could not be retrieved on 2026-09-16, the connection failing, so this entry rests on the absence of any international non-proprietary name and on the matching negative findings in the European, United States and Canadian registers rather than on a national register match. What is documented is enforcement against this product category. On 2026-06-22 the medicines agency, the customs authority and the national anti-doping body jointly checked 46 consignments of peptide preparations; 23 were held back, 21 of them classed as doping material and two as medicines, with around 80 percent of the consignments arriving from one country. The national doping list of 2026 carries mechano growth factors by name in its section S2.3.","date":"2026-06-30","source":"https://www.swissmedic.ch/"}],"devStage":"preclinical","strongestEvidence":"animal","wada":{"status":"prohibited","section":"S2.3","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[],"sameAs":[],"lastVerified":"2026-09-16","version":"1.0","published":true,"locale":"en","title":"Mechano Growth Factor (MGF): what the studies show, status and safety","summary":"Mechano growth factor is two things under one name. The body makes a splice variant of the growth factor IGF-1, called IGF-1Ec, when muscle is stretched or damaged. The grey market sells a synthetic 24-building-block piece of that protein, usually carrying a swapped building block. No human being has ever received either one in a study of any kind, and laboratory tests show the short peptide does not switch on the IGF-1 receptor. Sport bans it by name, and German law sets one of its lowest criminal thresholds for it.","updated":"2026-09-16","url":"https://mypep.app/peptides/mgf"}